{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:07:31Z","timestamp":1778684851028,"version":"3.51.4"},"reference-count":163,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40120-026-00907-1","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:38:12Z","timestamp":1773369492000},"page":"863-886","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Anti-CD20 Therapies on Cytokine, Chemokine and Adhesion Molecule Dynamics in Multiple Sclerosis: A Narrative Review"],"prefix":"10.1007","volume":"15","author":[{"given":"Marc","family":"Messner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef-Martin","family":"Mitterwallner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Unterhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Wipfler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Harrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Moser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"5 Suppl 14","key":"907_CR1","first-page":"66","volume":"26","author":"AJ Grillo-L\u00f3pez","year":"1999","unstructured":"Grillo-L\u00f3pez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999;26(5 Suppl 14):66\u201373.","journal-title":"Semin Oncol"},{"issue":"3","key":"907_CR2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/ana.21363","volume":"63","author":"A Bar-Or","year":"2008","unstructured":"Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase\u00a0I trial. Ann Neurol. 2008;63(3):395\u2013400. https:\/\/doi.org\/10.1002\/ana.21363.","journal-title":"Ann Neurol"},{"key":"907_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1363102","volume":"15","author":"A Dabkowska","year":"2024","unstructured":"Dabkowska A, Domka K, Firczuk M. Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T\u00a0cells. Front Immunol. 2024;15:1363102. https:\/\/doi.org\/10.3389\/fimmu.2024.1363102.","journal-title":"Front Immunol"},{"issue":"1","key":"907_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1389201003379059","volume":"1","author":"AJ Grillo-L\u00f3pez","year":"2000","unstructured":"Grillo-L\u00f3pez AJ, White CA, Dallaire BK, et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol. 2000;1(1):1\u20139. https:\/\/doi.org\/10.2174\/1389201003379059.","journal-title":"Curr Pharm Biotechnol"},{"issue":"4","key":"907_CR5","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.4049\/jimmunol.125.4.1678","volume":"125","author":"P Stashenko","year":"1980","unstructured":"Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125(4):1678\u201385.","journal-title":"J Immunol"},{"issue":"6","key":"907_CR6","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1073\/pnas.78.6.3848","volume":"78","author":"P Stashenko","year":"1981","unstructured":"Stashenko P, Nadler LM, Hardy R, Schlossman SF. Expression of cell surface markers after human B lymphocyte activation. Proc Natl Acad Sci U S A. 1981;78(6):3848\u201352. https:\/\/doi.org\/10.1073\/pnas.78.6.3848.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"907_CR7","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1182\/blood.V70.5.1316.1316","volume":"70","author":"MR Loken","year":"1987","unstructured":"Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. Blood. 1987;70(5):1316\u201324.","journal-title":"Blood"},{"issue":"6","key":"907_CR8","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","volume":"105","author":"G Pavlasova","year":"2020","unstructured":"Pavlasova G, Mraz M. The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy. Haematologica. 2020;105(6):1494\u2013506. https:\/\/doi.org\/10.3324\/haematol.2019.243543.","journal-title":"Haematologica"},{"key":"907_CR9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01469-2021","author":"CM Pr\u00eale","year":"2022","unstructured":"Pr\u00eale CM, Miles T, Pearce DR, et al. Plasma cell but not CD20-mediated B-cell depletion protects from bleomycin-induced lung fibrosis. Eur Respir J. 2022. https:\/\/doi.org\/10.1183\/13993003.01469-2021.","journal-title":"Eur Respir J"},{"issue":"1","key":"907_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/nyas.13577","volume":"1415","author":"M Uzzan","year":"2018","unstructured":"Uzzan M, Ko HM, Rosenstein AK, Pourmand K, Colombel JF, Mehandru S. Efficient long-term depletion of CD20(+) B\u00a0cells by rituximab does not affect gut-resident plasma cells. Ann N Y Acad Sci. 2018;1415(1):5\u201310. https:\/\/doi.org\/10.1111\/nyas.13577.","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"907_CR11","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676\u201388. https:\/\/doi.org\/10.1056\/NEJMoa0706383.","journal-title":"N Engl J Med"},{"issue":"3","key":"907_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1601277.","journal-title":"N Engl J Med"},{"issue":"3","key":"907_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1606468.","journal-title":"N Engl J Med"},{"issue":"9","key":"907_CR14","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000213574","volume":"104","author":"SD Newsome","year":"2025","unstructured":"Newsome SD, Krzystanek E, Selmaj KW, et al. Subcutaneous ocrelizumab in patients with multiple sclerosis: results of the phase\u00a03 OCARINA II study. Neurology. 2025;104(9):e213574. https:\/\/doi.org\/10.1212\/wnl.0000000000213574.","journal-title":"Neurology"},{"issue":"12","key":"907_CR15","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/s1474-4422(20)30342-2","volume":"19","author":"JS Wolinsky","year":"2020","unstructured":"Wolinsky JS, Arnold DL, Brochet B, et al. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase\u00a03 trial. Lancet Neurol. 2020;19(12):998\u20131009. https:\/\/doi.org\/10.1016\/s1474-4422(20)30342-2.","journal-title":"Lancet Neurol"},{"issue":"6","key":"907_CR16","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1917246.","journal-title":"N Engl J Med"},{"issue":"12","key":"907_CR17","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1136\/ard.2011.151522","volume":"70","author":"PC Taylor","year":"2011","unstructured":"Taylor PC, Quattrocchi E, Mallett S, Kurrasch R, Petersen J, Chang DJ. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis. 2011;70(12):2119\u201325. https:\/\/doi.org\/10.1136\/ard.2011.151522.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"907_CR18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/rheumatology\/keaa234","volume":"60","author":"JS Smolen","year":"2021","unstructured":"Smolen JS, Cohen SB, Tony HP, et al. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial. Rheumatology (Oxford). 2021;60(1):256\u201362. https:\/\/doi.org\/10.1093\/rheumatology\/keaa234.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"907_CR19","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1093\/rheumatology\/keac024","volume":"61","author":"MHM Wientjes","year":"2022","unstructured":"Wientjes MHM, Gijzen TMG, den Broeder N, et al. Drug levels, anti-drug antibodies and B-cell counts were not predictive of response in rheumatoid arthritis patients on (ultra-)low-dose\u2002rituximab. Rheumatology (Oxford). 2022;61(10):3974\u201380. https:\/\/doi.org\/10.1093\/rheumatology\/keac024.","journal-title":"Rheumatology (Oxford)"},{"issue":"15","key":"907_CR20","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","volume":"392","author":"RA Furie","year":"2025","unstructured":"Furie RA, Rovin BH, Garg JP, et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med. 2025;392(15):1471\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2410965.","journal-title":"N Engl J Med"},{"issue":"17","key":"907_CR21","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood.2020008750","volume":"137","author":"S Le Gouill","year":"2021","unstructured":"Le Gouill S, Ghesqui\u00e8res H, Oberic L, et al. Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase\u00a03 study by LYSA. Blood. 2021;137(17):2307\u201320. https:\/\/doi.org\/10.1182\/blood.2020008750.","journal-title":"Blood"},{"issue":"14","key":"907_CR22","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1614598.","journal-title":"N Engl J Med"},{"issue":"7","key":"907_CR23","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1200\/jco.2017.74.5083","volume":"36","author":"M Shadman","year":"2018","unstructured":"Shadman M, Li H, Rimsza L, et al. Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus (131)I-tositumomab: long-term follow-up of phase\u00a0III randomized study SWOG-S0016. J Clin Oncol. 2018;36(7):697\u2013703. https:\/\/doi.org\/10.1200\/jco.2017.74.5083.","journal-title":"J Clin Oncol"},{"issue":"5","key":"907_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013247.pub2","volume":"5","author":"M Lin","year":"2022","unstructured":"Lin M, Zhang J, Zhang Y, Luo J, Shi S. Ocrelizumab for multiple sclerosis. Cochrane Database Syst Rev. 2022;5(5):CD013247. https:\/\/doi.org\/10.1002\/14651858.CD013247.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"907_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/14712598.2020.1822318","volume":"21","author":"C Klein","year":"2021","unstructured":"Klein C, Jamois C, Nielsen T. Anti-CD20 treatment for B-cell malignancies: current status and future directions. Expert Opin Biol Ther. 2021;21(2):161\u201381. https:\/\/doi.org\/10.1080\/14712598.2020.1822318.","journal-title":"Expert Opin Biol Ther"},{"key":"907_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ibneur.2021.08.003","volume":"11","author":"MZI Asha","year":"2021","unstructured":"Asha MZI, Al-Asaad Y, Khalil SFH. The comparative efficacy and safety of anti-CD20 monoclonal antibodies for relapsing-remitting multiple sclerosis: a network meta-analysis. IBRO Neurosci Rep. 2021;11:103\u201311. https:\/\/doi.org\/10.1016\/j.ibneur.2021.08.003.","journal-title":"IBRO Neurosci Rep"},{"issue":"6","key":"907_CR27","first-page":"676","volume":"2","author":"P Boross","year":"2012","unstructured":"Boross P, Leusen JH. Mechanisms of action of CD20 antibodies. Am J Cancer Res. 2012;2(6):676\u201390.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"907_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00262-001-0247-1","volume":"51","author":"PM Cardarelli","year":"2002","unstructured":"Cardarelli PM, Quinn M, Buckman D, et al. Binding to CD20 by anti-B1 antibody or F(ab\u2019)(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother. 2002;51(1):15\u201324. https:\/\/doi.org\/10.1007\/s00262-001-0247-1.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"907_CR29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2207291120","volume":"120","author":"K Shinoda","year":"2023","unstructured":"Shinoda K, Li R, Rezk A, et al. Differential effects of anti-CD20 therapy on CD4 and CD8 T\u00a0cells and implication of CD20-expressing CD8 T\u00a0cells in MS disease activity. Proc Natl Acad Sci U S A. 2023;120(3):e2207291120. https:\/\/doi.org\/10.1073\/pnas.2207291120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"907_CR30","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200083","author":"S Ho","year":"2023","unstructured":"Ho S, Oswald E, Wong HK, et al. Ocrelizumab treatment modulates B-cell regulating factors in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023. https:\/\/doi.org\/10.1212\/nxi.0000000000200083.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"907_CR31","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ncrna.2025.05.009","volume":"13","author":"B De Felice","year":"2025","unstructured":"De Felice B, Signoriello E, Montanino C, et al. Role of ocrelizumab in modulating gene and microRNA expression in multiple sclerosis. Noncoding RNA Res. 2025;13:174\u201383. https:\/\/doi.org\/10.1016\/j.ncrna.2025.05.009.","journal-title":"Noncoding RNA Res"},{"issue":"1","key":"907_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-02900-z","volume":"20","author":"C Rodriguez-Mogeda","year":"2023","unstructured":"Rodriguez-Mogeda C, van Lierop Z, van der Pol SMA, et al. Extended interval dosing of ocrelizumab modifies the repopulation of B\u00a0cells without altering the clinical efficacy in multiple sclerosis. J Neuroinflammation. 2023;20(1):215. https:\/\/doi.org\/10.1186\/s12974-023-02900-z.","journal-title":"J Neuroinflammation"},{"issue":"9","key":"907_CR33","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1177\/0091270007305297","volume":"47","author":"F Breedveld","year":"2007","unstructured":"Breedveld F, Agarwal S, Yin M, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol. 2007;47(9):1119\u201328. https:\/\/doi.org\/10.1177\/0091270007305297.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"907_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/ar3901","volume":"14","author":"HP Brezinschek","year":"2012","unstructured":"Brezinschek HP, Rainer F, Brickmann K, Graninger WB. B lymphocyte-typing for prediction of clinical response to rituximab. Arthritis Res Ther. 2012;14(4):R161. https:\/\/doi.org\/10.1186\/ar3901.","journal-title":"Arthritis Res Ther"},{"key":"907_CR35","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200152","author":"R Claverie","year":"2023","unstructured":"Claverie R, Perriguey M, Rico A, et al. Efficacy of rituximab outlasts B-cell repopulation in multiple sclerosis: time to rethink dosing? Neurol Neuroimmunol Neuroinflamm. 2023. https:\/\/doi.org\/10.1212\/nxi.0000000000200152.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"39","key":"907_CR36","doi-asserted-by":"publisher","first-page":"9773","DOI":"10.1073\/pnas.1810470115","volume":"115","author":"D H\u00e4usler","year":"2018","unstructured":"H\u00e4usler D, H\u00e4usser-Kinzel S, Feldmann L, et al. Functional characterization of reappearing B\u00a0cells after anti-CD20 treatment of CNS autoimmune disease. Proc Natl Acad Sci U S A. 2018;115(39):9773\u20138. https:\/\/doi.org\/10.1073\/pnas.1810470115.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"907_CR37","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200250","volume":"11","author":"G Abbadessa","year":"2024","unstructured":"Abbadessa G, Lepore MT, Bruzzaniti S, et al. Ocrelizumab alters cytotoxic lymphocyte function while reducing EBV-specific CD8(+) T-cell proliferation in patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2024;11(4):e200250. https:\/\/doi.org\/10.1212\/nxi.0000000000200250.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"907_CR38","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000940","author":"JI Fern\u00e1ndez-Velasco","year":"2021","unstructured":"Fern\u00e1ndez-Velasco JI, Kuhle J, Monreal E, et al. Effect of ocrelizumab in blood leukocytes of patients with primary progressive MS. Neurol Neuroimmunol Neuroinflamm. 2021. https:\/\/doi.org\/10.1212\/nxi.0000000000000940.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"907_CR39","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200091","author":"A Garcia","year":"2023","unstructured":"Garcia A, Dugast E, Shah S, et al. Immune profiling reveals the T-cell effect of ocrelizumab in early relapsing-remitting multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023. https:\/\/doi.org\/10.1212\/nxi.0000000000200091.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1-2","key":"907_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.06.029","volume":"180","author":"AH Cross","year":"2006","unstructured":"Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B\u00a0cells and T\u00a0cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006;180(1\u20132):63\u201370. https:\/\/doi.org\/10.1016\/j.jneuroim.2006.06.029.","journal-title":"J Neuroimmunol"},{"issue":"5","key":"907_CR41","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/acn3.70042","volume":"12","author":"S Yang","year":"2025","unstructured":"Yang S, Zhang TX, Liu J, et al. Reconstitution of CXCR3(+) CCR6(+) Th17.1-like T\u00a0cells in response to ofatumumab therapy in patients with multiple sclerosis. Ann Clin Transl Neurol. 2025;12(5):1043\u201353. https:\/\/doi.org\/10.1002\/acn3.70042.","journal-title":"Ann Clin Transl Neurol"},{"key":"907_CR42","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200004","author":"M von Essen Mr","year":"2022","unstructured":"von Essen Mr M, Hansen RH, H\u00f8jgaard C, Ammitzb\u00f8ll C, Wiendl H, Sellebjerg F. Ofatumumab modulates inflammatory T\u00a0cell responses and migratory potential in patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022. https:\/\/doi.org\/10.1212\/nxi.0000000000200004.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"907_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102647","volume":"19","author":"T Moser","year":"2020","unstructured":"Moser T, Akgun K, Proschmann U, Sellner J, Ziemssen T. The role of TH17 cells in multiple sclerosis: therapeutic implications. Autoimmun Rev. 2020;19(10):102647. https:\/\/doi.org\/10.1016\/j.autrev.2020.102647.","journal-title":"Autoimmun Rev"},{"key":"907_CR44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","volume":"16","author":"D Baker","year":"2017","unstructured":"Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K. Memory B\u00a0cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine. 2017;16:41\u201350. https:\/\/doi.org\/10.1016\/j.ebiom.2017.01.042.","journal-title":"EBioMedicine"},{"issue":"2","key":"907_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192516","volume":"13","author":"P de Flon","year":"2018","unstructured":"de Flon P, S\u00f6derstr\u00f6m L, Laurell K, et al. Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls. PLoS ONE. 2018;13(2):e0192516. https:\/\/doi.org\/10.1371\/journal.pone.0192516.","journal-title":"PLoS ONE"},{"issue":"5","key":"907_CR46","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1084\/jem.20111675","volume":"209","author":"TA Barr","year":"2012","unstructured":"Barr TA, Shen P, Brown S, et al. B\u00a0cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B\u00a0cells. J Exp Med. 2012;209(5):1001\u201310. https:\/\/doi.org\/10.1084\/jem.20111675.","journal-title":"J Exp Med"},{"key":"907_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1278250","volume":"14","author":"S Li","year":"2023","unstructured":"Li S, Zhang Z, Liu Z. Therapeutic effect of ofatumumab in patients with myasthenia gravis: immunoregulation of follicular T helper cells and T helper type\u00a017 cells. Front Neurol. 2023;14:1278250. https:\/\/doi.org\/10.3389\/fneur.2023.1278250.","journal-title":"Front Neurol"},{"issue":"19","key":"907_CR48","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1182\/blood-2008-12-197053","volume":"113","author":"M Bower","year":"2009","unstructured":"Bower M, Veraitch O, Szydlo R, et al. Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. Blood. 2009;113(19):4521\u20134. https:\/\/doi.org\/10.1182\/blood-2008-12-197053.","journal-title":"Blood"},{"key":"907_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/btt.s27840","volume":"6","author":"E Hasan","year":"2012","unstructured":"Hasan E, Olusi S, Al-Awadhi A, Mokaddem K, Sharma P, George S. Effects of rituximab treatment on the serum concentrations of vitamin\u00a0D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis. Biologics. 2012;6:31\u20135. https:\/\/doi.org\/10.2147\/btt.s27840.","journal-title":"Biologics"},{"key":"907_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cells11121959","author":"M Boziki","year":"2022","unstructured":"Boziki M, Bakirtzis C, Sintila SA, et al. Ocrelizumab in patients with active primary progressive multiple sclerosis: clinical outcomes and immune markers of treatment response. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11121959.","journal-title":"Cells"},{"key":"907_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232213759","author":"K Akg\u00fcn","year":"2022","unstructured":"Akg\u00fcn K, Behrens J, Schriefer D, Ziemssen T. Acute effects of ocrelizumab infusion in multiple sclerosis patients. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232213759.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"907_CR52","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1002\/art.38798","volume":"66","author":"JD Jones","year":"2014","unstructured":"Jones JD, Hamilton BJ, Skopelja S, Rigby WF. Induction of interleukin-6 production by rituximab in human B\u00a0cells. Arthritis Rheumatol. 2014;66(11):2938\u201346. https:\/\/doi.org\/10.1002\/art.38798.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"907_CR53","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1097\/01.tp.0000112934.12622.2b","volume":"77","author":"CA Vieira","year":"2004","unstructured":"Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation. 2004;77(4):542\u20138. https:\/\/doi.org\/10.1097\/01.tp.0000112934.12622.2b.","journal-title":"Transplantation"},{"issue":"10","key":"907_CR54","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295. https:\/\/doi.org\/10.1101\/cshperspect.a016295.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"3","key":"907_CR55","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000515595","volume":"28","author":"M Shajarian","year":"2021","unstructured":"Shajarian M, Alsahebfosoul F, Etemadifar M. The effect of IFN-\u03b2 treatment on plasma levels of BDNF and IL-6 in relapsing-remitting multiple sclerosis patients. NeuroImmunoModulation. 2021;28(3):150\u20137. https:\/\/doi.org\/10.1159\/000515595.","journal-title":"NeuroImmunoModulation"},{"issue":"8","key":"907_CR56","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1056\/NEJMoa2201302","volume":"387","author":"JS Smolen","year":"2022","unstructured":"Smolen JS, Feist E, Fatenejad S, et al. Olokizumab versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2022;387(8):715\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2201302.","journal-title":"N Engl J Med"},{"issue":"9","key":"907_CR57","doi-asserted-by":"publisher","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","volume":"37","author":"N Kumari","year":"2016","unstructured":"Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016;37(9):11553\u201372. https:\/\/doi.org\/10.1007\/s13277-016-5098-7.","journal-title":"Tumour Biol"},{"issue":"4","key":"907_CR58","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/ana.21939","volume":"67","author":"A Bar-Or","year":"2010","unstructured":"Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol. 2010;67(4):452\u201361. https:\/\/doi.org\/10.1002\/ana.21939.","journal-title":"Ann Neurol"},{"issue":"3","key":"907_CR59","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/ana.22081","volume":"68","author":"MS Weber","year":"2010","unstructured":"Weber MS, Prod\u2019homme T, Patarroyo JC, et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol. 2010;68(3):369\u201383. https:\/\/doi.org\/10.1002\/ana.22081.","journal-title":"Ann Neurol"},{"issue":"3","key":"907_CR60","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1177\/1352458513498128","volume":"20","author":"S Rossi","year":"2014","unstructured":"Rossi S, Motta C, Studer V, et al. Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration. Mult Scler. 2014;20(3):304\u201312. https:\/\/doi.org\/10.1177\/1352458513498128.","journal-title":"Mult Scler"},{"key":"907_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-8-146","volume":"8","author":"K Lehmann-Horn","year":"2011","unstructured":"Lehmann-Horn K, Schleich E, Hertzenberg D, et al. Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders. J Neuroinflammation. 2011;8:146. https:\/\/doi.org\/10.1186\/1742-2094-8-146.","journal-title":"J Neuroinflammation"},{"issue":"6","key":"907_CR62","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/art.30314","volume":"63","author":"FL van de Veerdonk","year":"2011","unstructured":"van de Veerdonk FL, Lauwerys B, Marijnissen RJ, et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum. 2011;63(6):1507\u201316. https:\/\/doi.org\/10.1002\/art.30314.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"907_CR63","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1128\/iai.64.2.535-541.1996","volume":"64","author":"P Jacobs","year":"1996","unstructured":"Jacobs P, Radzioch D, Stevenson MM. A Th1-associated increase in tumor necrosis factor alpha expression in the spleen correlates with resistance to blood-stage malaria in mice. Infect Immun. 1996;64(2):535\u201341. https:\/\/doi.org\/10.1128\/iai.64.2.535-541.1996.","journal-title":"Infect Immun"},{"issue":"13","key":"907_CR64","doi-asserted-by":"publisher","first-page":"5360","DOI":"10.1073\/pnas.1015476108","volume":"108","author":"M Fei","year":"2011","unstructured":"Fei M, Bhatia S, Oriss TB, et al. TNF-alpha from inflammatory dendritic cells (DCs) regulates lung IL-17A\/IL-5 levels and neutrophilia versus eosinophilia during persistent fungal infection. Proc Natl Acad Sci U S A. 2011;108(13):5360\u20135. https:\/\/doi.org\/10.1073\/pnas.1015476108.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"907_CR65","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/bf01540972","volume":"16","author":"A Jewett","year":"1996","unstructured":"Jewett A, Gan XH, Lebow LT, Bonavida B. Differential secretion of TNF-alpha and IFN-gamma by human peripheral blood-derived NK subsets and association with functional maturation. J Clin Immunol. 1996;16(1):46\u201354. https:\/\/doi.org\/10.1007\/bf01540972.","journal-title":"J Clin Immunol"},{"issue":"1","key":"907_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03193-6","volume":"21","author":"V Mazziotti","year":"2024","unstructured":"Mazziotti V, Crescenzo F, Turano E, et al. The contribution of tumor necrosis factor to multiple sclerosis: a possible role in progression independent of relapse? J Neuroinflammation. 2024;21(1):209. https:\/\/doi.org\/10.1186\/s12974-024-03193-6.","journal-title":"J Neuroinflammation"},{"issue":"2","key":"907_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090117","volume":"9","author":"SK Williams","year":"2014","unstructured":"Williams SK, Maier O, Fischer R, et al. Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis. PLoS ONE. 2014;9(2):e90117. https:\/\/doi.org\/10.1371\/journal.pone.0090117.","journal-title":"PLoS ONE"},{"issue":"4","key":"907_CR68","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-017-0742-1","volume":"17","author":"E Kemanetzoglou","year":"2017","unstructured":"Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-\u03b1 blockers. Curr Neurol Neurosci Rep. 2017;17(4):36. https:\/\/doi.org\/10.1007\/s11910-017-0742-1.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"10","key":"907_CR69","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18847","volume":"13","author":"M Zahid","year":"2021","unstructured":"Zahid M, Busmail A, Penumetcha SS, et al. Tumor necrosis factor alpha blockade and multiple sclerosis: exploring new avenues. Cureus. 2021;13(10):e18847. https:\/\/doi.org\/10.7759\/cureus.18847.","journal-title":"Cureus"},{"issue":"10","key":"907_CR70","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.4049\/jimmunol.178.10.6092","volume":"178","author":"M Duddy","year":"2007","unstructured":"Duddy M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory and naive human B\u00a0cell subsets and implication in multiple sclerosis. J Immunol. 2007;178(10):6092\u20139. https:\/\/doi.org\/10.4049\/jimmunol.178.10.6092.","journal-title":"J Immunol"},{"issue":"1\u20132","key":"907_CR71","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0165-5728(96)00032-x","volume":"66","author":"D Matusevicius","year":"1996","unstructured":"Matusevicius D, Navikas V, S\u00f6derstr\u00f6m M, et al. Multiple sclerosis: the proinflammatory cytokines lymphotoxin-alpha and tumour necrosis factor-alpha are upregulated in cerebrospinal fluid mononuclear cells. J Neuroimmunol. 1996;66(1\u20132):115\u201323. https:\/\/doi.org\/10.1016\/0165-5728(96)00032-x.","journal-title":"J Neuroimmunol"},{"issue":"12","key":"907_CR72","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1093\/brain\/awac232","volume":"145","author":"RE James Bates","year":"2022","unstructured":"James Bates RE, Browne E, Schalks R, et al. Lymphotoxin-alpha expression in the meninges causes lymphoid tissue formation and neurodegeneration. Brain. 2022;145(12):4287\u2013307. https:\/\/doi.org\/10.1093\/brain\/awac232.","journal-title":"Brain"},{"issue":"8","key":"907_CR73","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/j.1600-6143.2004.00502.x","volume":"4","author":"A Agarwal","year":"2004","unstructured":"Agarwal A, Vieira CA, Book BK, Sidner RA, Fineberg NS, Pescovitz MD. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am J Transplant. 2004;4(8):1357\u201360. https:\/\/doi.org\/10.1111\/j.1600-6143.2004.00502.x.","journal-title":"Am J Transplant"},{"issue":"6","key":"907_CR74","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1002\/hep.23238","volume":"50","author":"Y Moritoki","year":"2009","unstructured":"Moritoki Y, Lian ZX, Lindor K, et al. B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice. Hepatology. 2009;50(6):1893\u2013903. https:\/\/doi.org\/10.1002\/hep.23238.","journal-title":"Hepatology"},{"issue":"4","key":"907_CR75","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/rheumatology\/kes365","volume":"52","author":"YM Chen","year":"2013","unstructured":"Chen YM, Chen HH, Lai KL, Hung WT, Lan JL, Chen DY. The effects of rituximab therapy on released interferon-\u03b3 levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection. Rheumatology (Oxford). 2013;52(4):697\u2013704. https:\/\/doi.org\/10.1093\/rheumatology\/kes365.","journal-title":"Rheumatology (Oxford)"},{"key":"907_CR76","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1365-2141.2009.07911.x","volume":"1","author":"R Kruse-Jarres","year":"2010","unstructured":"Kruse-Jarres R, Fang J, Leissinger CA, Ganapamo F. Rituximab therapy modulates IFN-gamma and IL-4 gene expression in a patient with acquired haemophilia A. Br J Haematol. 2010;1:176\u20138.","journal-title":"Br J Haematol"},{"issue":"8","key":"907_CR77","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00262-011-1168-2","volume":"61","author":"D Stroopinsky","year":"2012","unstructured":"Stroopinsky D, Katz T, Rowe JM, Melamed D, Avivi I. Rituximab-induced direct inhibition of T-cell activation. Cancer Immunol Immunother. 2012;61(8):1233\u201341. https:\/\/doi.org\/10.1007\/s00262-011-1168-2.","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"907_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102647","volume":"19","author":"T Moser","year":"2020","unstructured":"Moser T, Akg\u00fcn K, Proschmann U, Sellner J, Ziemssen T. The role of TH17 cells in multiple sclerosis: therapeutic implications. Autoimmun Rev. 2020;19(10):102647. https:\/\/doi.org\/10.1016\/j.autrev.2020.102647.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"907_CR79","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/135245850100700502","volume":"7","author":"S Skurkovich","year":"2001","unstructured":"Skurkovich S, Boiko A, Beliaeva I, et al. Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis. Mult Scler. 2001;7(5):277\u201384. https:\/\/doi.org\/10.1177\/135245850100700502.","journal-title":"Mult Scler"},{"key":"907_CR80","doi-asserted-by":"publisher","unstructured":"Arellano G, Ottum PA, Reyes LI, Burgos PI, Naves R. Stage-specific role of interferon-gamma in experimental autoimmune encephalomyelitis and multiple sclerosis. Front Immunol. 2015;6:492. https:\/\/doi.org\/10.3389\/fimmu.2015.00492.","DOI":"10.3389\/fimmu.2015.00492"},{"issue":"1","key":"907_CR81","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40364-022-00415-y","volume":"10","author":"F Xiong","year":"2022","unstructured":"Xiong F, Wang Q, Wu G-h, Liu W-z, Wang B, Chen Y-j. Direct and indirect effects of IFN-\u03b12b in malignancy treatment: not only an archer but also an arrow. Biomark Res. 2022;10(1):69. https:\/\/doi.org\/10.1186\/s40364-022-00415-y.","journal-title":"Biomark Res"},{"key":"907_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.109894","volume":"259","author":"L Beckers","year":"2024","unstructured":"Beckers L, Baeten P, Popescu V, et al. Alterations in the innate and adaptive immune system in a real-world cohort of multiple sclerosis patients treated with ocrelizumab. Clin Immunol. 2024;259:109894. https:\/\/doi.org\/10.1016\/j.clim.2024.109894.","journal-title":"Clin Immunol"},{"key":"907_CR83","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4963950","volume":"2016","author":"EV Tchetina","year":"2016","unstructured":"Tchetina EV, Pivanova AN, Markova GA, et al. Rituximab downregulates gene expression associated with cell proliferation, survival, and proteolysis in the peripheral blood from rheumatoid arthritis patients: a link between high baseline autophagy-related ULK1 expression and improved pain control. Arthritis. 2016;2016:4963950. https:\/\/doi.org\/10.1155\/2016\/4963950.","journal-title":"Arthritis"},{"issue":"1","key":"907_CR84","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/ana.22512","volume":"71","author":"S Rossi","year":"2012","unstructured":"Rossi S, Furlan R, De Chiara V, et al. Interleukin-1\u03b2 causes synaptic hyperexcitability in multiple sclerosis. Ann Neurol. 2012;71(1):76\u201383. https:\/\/doi.org\/10.1002\/ana.22512.","journal-title":"Ann Neurol"},{"issue":"7","key":"907_CR85","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1084\/jem.20060285","volume":"203","author":"C Sutton","year":"2006","unstructured":"Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T\u00a0cells that mediate autoimmune encephalomyelitis. J Exp Med. 2006;203(7):1685\u201391. https:\/\/doi.org\/10.1084\/jem.20060285.","journal-title":"J Exp Med"},{"key":"907_CR86","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1146\/annurev.iy.13.040195.001343","volume":"13","author":"G Trinchieri","year":"1995","unstructured":"Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol. 1995;13:251\u201376. https:\/\/doi.org\/10.1146\/annurev.iy.13.040195.001343.","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"907_CR87","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/s1359-6101(03)00043-1","volume":"14","author":"WT Watford","year":"2003","unstructured":"Watford WT, Moriguchi M, Morinobu A, O\u2019Shea JJ. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev. 2003;14(5):361\u20138. https:\/\/doi.org\/10.1016\/s1359-6101(03)00043-1.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"3","key":"907_CR88","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/imm.12212","volume":"142","author":"C D\u00edaz-Torn\u00e9","year":"2014","unstructured":"D\u00edaz-Torn\u00e9 C, de Ortiz Juana MA, Geli C, et al. Rituximab-induced interleukin-15 reduction associated with clinical improvement in rheumatoid arthritis. Immunology. 2014;142(3):354\u201362. https:\/\/doi.org\/10.1111\/imm.12212.","journal-title":"Immunology"},{"issue":"11","key":"907_CR89","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1172\/jci128475","volume":"129","author":"E Beltr\u00e1n","year":"2019","unstructured":"Beltr\u00e1n E, Gerdes LA, Hansen J, et al. Early adaptive immune activation detected in monozygotic twins with prodromal multiple sclerosis. J Clin Invest. 2019;129(11):4758\u201368. https:\/\/doi.org\/10.1172\/jci128475.","journal-title":"J Clin Invest"},{"issue":"1-2","key":"907_CR90","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jns.2005.10.003","volume":"241","author":"M Rentzos","year":"2006","unstructured":"Rentzos M, Cambouri C, Rombos A, et al. IL-15 is elevated in serum and cerebrospinal fluid of patients with multiple sclerosis. J Neurol Sci. 2006;241(1\u20132):25\u20139. https:\/\/doi.org\/10.1016\/j.jns.2005.10.003.","journal-title":"J Neurol Sci"},{"issue":"2","key":"907_CR91","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/acn3.51965","volume":"11","author":"J Feige","year":"2024","unstructured":"Feige J, Moser T, Akg\u00fcn K, et al. Repeated iv anti-CD20 treatment in multiple sclerosis: long-term effects on peripheral immune cell subsets. Ann Clin Transl Neurol. 2024;11(2):450\u201365. https:\/\/doi.org\/10.1002\/acn3.51965.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"907_CR92","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12020-021-02965-x","volume":"76","author":"M Chen","year":"2022","unstructured":"Chen M, Zhang Q, Wei Y, Wan Q, Xu M, Chen X. Anti-CD20 therapy ameliorates \u03b2 cell function and rebalances Th17\/Treg cells in NOD mice. Endocrine. 2022;76(1):44\u201352. https:\/\/doi.org\/10.1007\/s12020-021-02965-x.","journal-title":"Endocrine"},{"issue":"7","key":"907_CR93","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/rheumatology\/keu004","volume":"53","author":"F Ciccia","year":"2014","unstructured":"Ciccia F, Guggino G, Rizzo A, et al. Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sj\u00f6gren\u2019s syndrome. Rheumatology. 2014;53(7):1313\u201320. https:\/\/doi.org\/10.1093\/rheumatology\/keu004.","journal-title":"Rheumatology"},{"issue":"6","key":"907_CR94","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1111\/ajt.12220","volume":"13","author":"EG Kamburova","year":"2013","unstructured":"Kamburova EG, Koenen HJ, Borgman KJ, ten Berge IJ, Joosten I, Hilbrands LB. A single dose of rituximab does not deplete B\u00a0cells in secondary lymphoid organs but alters phenotype and function. Am J Transplant. 2013;13(6):1503\u201311. https:\/\/doi.org\/10.1111\/ajt.12220.","journal-title":"Am J Transplant"},{"issue":"11","key":"907_CR95","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1016\/j.ajpath.2015.07.017","volume":"185","author":"KW Kim","year":"2015","unstructured":"Kim KW, Kim HR, Kim BM, Cho ML, Lee SH. Th17 cytokines regulate osteoclastogenesis in rheumatoid arthritis. Am J Pathol. 2015;185(11):3011\u201324. https:\/\/doi.org\/10.1016\/j.ajpath.2015.07.017.","journal-title":"Am J Pathol"},{"key":"907_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2025.111211","volume":"136","author":"E Madill","year":"2025","unstructured":"Madill E, Galetta K, Opeyemi O, et al. Safety and efficacy of anti-IL-17A use in multiple sclerosis and comorbid rheumatological disease: a multi-center exploratory study. J Clin Neurosci. 2025;136:111211. https:\/\/doi.org\/10.1016\/j.jocn.2025.111211.","journal-title":"J Clin Neurosci"},{"key":"907_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143394","author":"K Bunte","year":"2019","unstructured":"Bunte K, Beikler T. Th17 cells and the IL-23\/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20143394.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"907_CR98","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3109\/08820139.2014.930477","volume":"44","author":"M Shajarian","year":"2015","unstructured":"Shajarian M, Alsahebfosoul F, Etemadifar M, et al. IL-23 plasma level measurement in relapsing remitting multiple sclerosis (RRMS) patients compared to healthy subjects. Immunol Invest. 2015;44(1):36\u201344. https:\/\/doi.org\/10.3109\/08820139.2014.930477.","journal-title":"Immunol Invest"},{"key":"907_CR99","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.msard.2016.01.001","volume":"6","author":"J Topping","year":"2016","unstructured":"Topping J, Dobson R, Lapin S, et al. The effects of intrathecal rituximab on biomarkers in multiple sclerosis. Mult Scler Relat Disord. 2016;6:49\u201353. https:\/\/doi.org\/10.1016\/j.msard.2016.01.001.","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"907_CR100","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.2337\/db12-1175","volume":"62","author":"C Hu","year":"2013","unstructured":"Hu C, Ding H, Zhang X, Wong FS, Wen L. Combination treatment with anti-CD20 and oral anti-CD3 prevents and reverses autoimmune diabetes. Diabetes. 2013;62(8):2849\u201358. https:\/\/doi.org\/10.2337\/db12-1175.","journal-title":"Diabetes"},{"key":"907_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105004","volume":"79","author":"M Nowak-Kiczmer","year":"2023","unstructured":"Nowak-Kiczmer M, Niedziela N, Czuba ZP, et al. A comparison of serum inflammatory parameters in progressive forms of multiple sclerosis. Mult Scler Relat Disord. 2023;79:105004. https:\/\/doi.org\/10.1016\/j.msard.2023.105004.","journal-title":"Mult Scler Relat Disord"},{"key":"907_CR102","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190418","author":"M Saraiva","year":"2020","unstructured":"Saraiva M, Vieira P, O\u2019Garra A. Biology and therapeutic potential of interleukin-10. J Exp Med. 2020. https:\/\/doi.org\/10.1084\/jem.20190418.","journal-title":"J Exp Med"},{"issue":"1","key":"907_CR103","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1615\/critrevimmunol.v32.i1.30","volume":"32","author":"SS Iyer","year":"2012","unstructured":"Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol. 2012;32(1):23\u201363. https:\/\/doi.org\/10.1615\/critrevimmunol.v32.i1.30.","journal-title":"Crit Rev Immunol"},{"issue":"7169","key":"907_CR104","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nature06306","volume":"450","author":"LW Collison","year":"2007","unstructured":"Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450(7169):566\u20139. https:\/\/doi.org\/10.1038\/nature06306.","journal-title":"Nature"},{"issue":"11","key":"907_CR105","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1002\/eji.200737810","volume":"37","author":"W Niedbala","year":"2007","unstructured":"Niedbala W, Wei XQ, Cai B, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T\u00a0cells and suppression of Th17 cells. Eur J Immunol. 2007;37(11):3021\u20139. https:\/\/doi.org\/10.1002\/eji.200737810.","journal-title":"Eur J Immunol"},{"issue":"6","key":"907_CR106","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nm.3554","volume":"20","author":"RX Wang","year":"2014","unstructured":"Wang RX, Yu CR, Dambuza IM, et al. Interleukin-35 induces regulatory B\u00a0cells that suppress autoimmune disease. Nat Med. 2014;20(6):633\u201341. https:\/\/doi.org\/10.1038\/nm.3554.","journal-title":"Nat Med"},{"issue":"7492","key":"907_CR107","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nature12979","volume":"507","author":"P Shen","year":"2014","unstructured":"Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B\u00a0cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 2014;507(7492):366\u201370. https:\/\/doi.org\/10.1038\/nature12979.","journal-title":"Nature"},{"issue":"1","key":"907_CR108","doi-asserted-by":"publisher","first-page":"258","DOI":"10.5114\/aoms.2020.101510","volume":"17","author":"H Ouyang","year":"2021","unstructured":"Ouyang H, Wen J, Song K. Decreased interleukin-35 levels and CD4(+)EBI3(+) T\u00a0cells in patients with type\u00a01 diabetes and the effects of the antibody against CD20 (rituximab). Arch Med Sci. 2021;17(1):258\u201361. https:\/\/doi.org\/10.5114\/aoms.2020.101510.","journal-title":"Arch Med Sci"},{"issue":"1","key":"907_CR109","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s12551-013-0133-z","volume":"6","author":"JL Silva-Filho","year":"2014","unstructured":"Silva-Filho JL, Caruso-Neves C, Pinheiro AAS. IL-4: an important cytokine in determining the fate of T\u00a0cells. Biophys Rev. 2014;6(1):111\u20138. https:\/\/doi.org\/10.1007\/s12551-013-0133-z.","journal-title":"Biophys Rev"},{"key":"907_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061257","author":"MA Boutet","year":"2019","unstructured":"Boutet MA, Nerviani A, Pitzalis C. IL-36, IL-37, and IL-38 cytokines in skin and joint inflammation: a comprehensive review of their therapeutic potential. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20061257.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"907_CR111","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s12026-022-09275-y","volume":"70","author":"P Fazeli","year":"2022","unstructured":"Fazeli P, Saeidnia M, Erfani M, Kalani M. An overview of the biological and multifunctional roles of IL-38 in different infectious diseases and COVID-19. Immunol Res. 2022;70(3):316\u201324. https:\/\/doi.org\/10.1007\/s12026-022-09275-y.","journal-title":"Immunol Res"},{"issue":"8","key":"907_CR112","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1073\/pnas.1121534109","volume":"109","author":"FL van de Veerdonk","year":"2012","unstructured":"van de Veerdonk FL, Stoeckman AK, Wu G, et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci U S A. 2012;109(8):3001\u20135. https:\/\/doi.org\/10.1073\/pnas.1121534109.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"907_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.intimp.2018.09.028","volume":"65","author":"WD Xu","year":"2018","unstructured":"Xu WD, Su LC, He CS, Huang AF. Plasma interleukin-38 in patients with rheumatoid arthritis. Int Immunopharmacol. 2018;65:1\u20137. https:\/\/doi.org\/10.1016\/j.intimp.2018.09.028.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"907_CR114","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/eji.201948390","volume":"51","author":"DM de Graaf","year":"2021","unstructured":"de Graaf DM, Jaeger M, van den Munckhof ICL, et al. Reduced concentrations of the B\u00a0cell cytokine interleukin 38 are associated with cardiovascular disease risk in overweight subjects. Eur J Immunol. 2021;51(3):662\u201371. https:\/\/doi.org\/10.1002\/eji.201948390.","journal-title":"Eur J Immunol"},{"issue":"Pt 4","key":"907_CR115","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/brain\/awm038","volume":"130","author":"R Magliozzi","year":"2007","unstructured":"Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130(Pt 4):1089\u2013104. https:\/\/doi.org\/10.1093\/brain\/awm038.","journal-title":"Brain"},{"key":"907_CR116","doi-asserted-by":"publisher","DOI":"10.1177\/2055217315623800","volume":"1","author":"E Alvarez","year":"2015","unstructured":"Alvarez E, Piccio L, Mikesell RJ, et al. Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures. Mult Scler J Exp Transl Clin. 2015;1:2055217315623800. https:\/\/doi.org\/10.1177\/2055217315623800.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"907_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00451","volume":"7","author":"M Mitsdoerffer","year":"2016","unstructured":"Mitsdoerffer M, Peters A. Tertiary lymphoid organs in central nervous system autoimmunity. Front Immunol. 2016;7:451. https:\/\/doi.org\/10.3389\/fimmu.2016.00451.","journal-title":"Front Immunol"},{"issue":"1","key":"907_CR118","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000520","volume":"6","author":"AR Pachner","year":"2019","unstructured":"Pachner AR, DiSano K, Royce DB, Gilli F. Clinical utility of a molecular signature in inflammatory demyelinating disease. Neurol Neuroimmunol Neuroinflamm. 2019;6(1):e520. https:\/\/doi.org\/10.1212\/nxi.0000000000000520.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"907_CR119","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10092099","author":"A Pachner","year":"2022","unstructured":"Pachner A. The brave new world of early treatment of multiple sclerosis: using the molecular biomarkers CXCL13 and neurofilament light to optimize immunotherapy. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10092099.","journal-title":"Biomedicines"},{"issue":"6","key":"907_CR120","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1001\/archneurol.2010.99","volume":"67","author":"L Piccio","year":"2010","unstructured":"Piccio L, Naismith RT, Trinkaus K, et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol. 2010;67(6):707\u201314. https:\/\/doi.org\/10.1001\/archneurol.2010.99.","journal-title":"Arch Neurol"},{"issue":"4","key":"907_CR121","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1001\/jamaneurol.2024.0017","volume":"81","author":"AH Cross","year":"2024","unstructured":"Cross AH, Gelfand JM, Thebault S, et al. Emerging cerebrospinal fluid biomarkers of disease activity and progression in multiple sclerosis. JAMA Neurol. 2024;81(4):373\u201383. https:\/\/doi.org\/10.1001\/jamaneurol.2024.0017.","journal-title":"JAMA Neurol"},{"key":"907_CR122","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cyto.2018.02.012","volume":"109","author":"N Karin","year":"2018","unstructured":"Karin N, Razon H. Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity. Cytokine. 2018;109:24\u20138. https:\/\/doi.org\/10.1016\/j.cyto.2018.02.012.","journal-title":"Cytokine"},{"issue":"3","key":"907_CR123","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41423-023-00974-6","volume":"20","author":"S Cambier","year":"2023","unstructured":"Cambier S, Gouwy M, Proost P. The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention. Cell Mol Immunol. 2023;20(3):217\u201351. https:\/\/doi.org\/10.1038\/s41423-023-00974-6.","journal-title":"Cell Mol Immunol"},{"key":"907_CR124","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061835","author":"A Suzumura","year":"2013","unstructured":"Suzumura A, Matsushita T, Tateishi T, et al. Characteristic cerebrospinal fluid cytokine\/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS ONE. 2013. https:\/\/doi.org\/10.1371\/journal.pone.0061835.","journal-title":"PLoS ONE"},{"issue":"4","key":"907_CR125","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1136\/jnnp.72.4.498","volume":"72","author":"DJ Mahad","year":"2002","unstructured":"Mahad DJ, Howell SJ, Woodroofe MN. Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2002;72(4):498\u2013502. https:\/\/doi.org\/10.1136\/jnnp.72.4.498.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"907_CR126","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1093\/rheumatology\/keq337","volume":"50","author":"S Rosengren","year":"2011","unstructured":"Rosengren S, Wei N, Kalunian KC, Kavanaugh A, Boyle DL. CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rheumatology (Oxford). 2011;50(3):603\u201310. https:\/\/doi.org\/10.1093\/rheumatology\/keq337.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"907_CR127","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10637-009-9223-y","volume":"27","author":"S Hasegawa","year":"2009","unstructured":"Hasegawa S, Kato H, Yamaguchi H, et al. Trastuzumab-induced CCL20 and interleukin-8 mRNA in human whole blood ex vivo. Invest New Drugs. 2009;27(6):579\u201382. https:\/\/doi.org\/10.1007\/s10637-009-9223-y.","journal-title":"Invest New Drugs"},{"issue":"2","key":"907_CR128","first-page":"91","volume":"15","author":"AM Witkowska","year":"2004","unstructured":"Witkowska AM, Borawska MH. Soluble intercellular adhesion molecule-1 (sICAM-1): an overview. Eur Cytokine Netw. 2004;15(2):91\u20138.","journal-title":"Eur Cytokine Netw"},{"issue":"12","key":"907_CR129","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.it.2012.07.004","volume":"33","author":"B Engelhardt","year":"2012","unstructured":"Engelhardt B, Ransohoff RM. Capture, crawl, cross: the T\u00a0cell code to breach the blood-brain barriers. Trends Immunol. 2012;33(12):579\u201389. https:\/\/doi.org\/10.1016\/j.it.2012.07.004.","journal-title":"Trends Immunol"},{"issue":"3","key":"907_CR130","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/ana.410410307","volume":"41","author":"P Rieckmann","year":"1997","unstructured":"Rieckmann P, Altenhofen B, Riegel A, Baudewig J, Felgenhauer K. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann Neurol. 1997;41(3):326\u201333. https:\/\/doi.org\/10.1002\/ana.410410307.","journal-title":"Ann Neurol"},{"issue":"9","key":"907_CR131","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899\u2013910. https:\/\/doi.org\/10.1056\/NEJMoa044397.","journal-title":"N Engl J Med"},{"issue":"45","key":"907_CR132","doi-asserted-by":"publisher","first-page":"32314","DOI":"10.1074\/jbc.M113.501668","volume":"288","author":"Y Yu","year":"2013","unstructured":"Yu Y, Sch\u00fcrpf T, Springer TA. How natalizumab binds and antagonizes \u03b14 integrins. J Biol Chem. 2013;288(45):32314\u201325. https:\/\/doi.org\/10.1074\/jbc.M113.501668.","journal-title":"J Biol Chem"},{"issue":"17","key":"907_CR133","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1212\/01.wnl.0000327671.91357.96","volume":"71","author":"M Krumbholz","year":"2008","unstructured":"Krumbholz M, Meinl I, K\u00fcmpfel T, Hohlfeld R, Meinl E. Natalizumab disproportionately increases circulating pre-B and B\u00a0cells in multiple sclerosis. Neurology. 2008;71(17):1350\u20134. https:\/\/doi.org\/10.1212\/01.wnl.0000327671.91357.96.","journal-title":"Neurology"},{"issue":"2","key":"907_CR134","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/art.21617","volume":"54","author":"MJ Leandro","year":"2006","unstructured":"Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JCW. Reconstitution of peripheral blood B\u00a0cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheumatism. 2006;54(2):613\u201320. https:\/\/doi.org\/10.1002\/art.21617.","journal-title":"Arthritis Rheumatism"},{"issue":"5","key":"907_CR135","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.kint.2019.12.025","volume":"97","author":"E Crickx","year":"2020","unstructured":"Crickx E, Weill J-C, Reynaud C-A, Mah\u00e9vas M. Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives. Kidney Int. 2020;97(5):885\u201393. https:\/\/doi.org\/10.1016\/j.kint.2019.12.025.","journal-title":"Kidney Int"},{"issue":"5","key":"907_CR136","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s10072-022-06582-y","volume":"44","author":"S Saidha","year":"2023","unstructured":"Saidha S, Bell J, Harold S, et al. Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis. Neurol Sci. 2023;44(5):1515\u201332. https:\/\/doi.org\/10.1007\/s10072-022-06582-y.","journal-title":"Neurol Sci"},{"key":"907_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105009","author":"E Alvarez","year":"2023","unstructured":"Alvarez E, Longbrake EE, Rammohan KW, Stankiewicz J, Hersh CM. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management. Mult Scler Relat Disord. 2023. https:\/\/doi.org\/10.1016\/j.msard.2023.105009.","journal-title":"Mult Scler Relat Disord"},{"key":"907_CR138","doi-asserted-by":"publisher","unstructured":"Elgenidy A, Abdelhalim NN, Al-Kurdi MA, et al. Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patients. Front Neurol. 2024;15https:\/\/doi.org\/10.3389\/fneur.2024.1380654.","DOI":"10.3389\/fneur.2024.1380654"},{"key":"907_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103560","author":"T Moser","year":"2022","unstructured":"Moser T, Otto F, O\u2019Sullivan C, et al. Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications \u2013 a pilot study. Mult Scler Relat Disord. 2022. https:\/\/doi.org\/10.1016\/j.msard.2022.103560.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"907_CR140","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3390\/neurolint14040075","volume":"14","author":"J Feige","year":"2022","unstructured":"Feige J, Berek K, Seiberl M, et al. Humoral response to SARS-CoV-2 antigen in patients treated with monoclonal anti-CD20 antibodies: it is not all about B cell recovery. Neurol Int. 2022;14(4):943\u201351. https:\/\/doi.org\/10.3390\/neurolint14040075.","journal-title":"Neurol Int"},{"key":"907_CR141","doi-asserted-by":"publisher","DOI":"10.1177\/17562864221092092","author":"T Moser","year":"2022","unstructured":"Moser T, O\u2019Sullivan C, Otto F, et al. Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study. Ther Adv Neurol Disord. 2022. https:\/\/doi.org\/10.1177\/17562864221092092.","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"907_CR142","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","volume":"27","author":"SA Apostolidis","year":"2021","unstructured":"Apostolidis SA, Kakara M, Painter MM, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med. 2021;27(11):1990\u20132001. https:\/\/doi.org\/10.1038\/s41591-021-01507-2.","journal-title":"Nat Med"},{"issue":"12","key":"907_CR143","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1182\/bloodadvances.2021004629","volume":"5","author":"A Vijenthira","year":"2021","unstructured":"Vijenthira A, Gong I, Betschel SD, Cheung M, Hicks LK. Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. Blood Adv. 2021;5(12):2624\u201343. https:\/\/doi.org\/10.1182\/bloodadvances.2021004629.","journal-title":"Blood Adv"},{"key":"907_CR144","doi-asserted-by":"publisher","unstructured":"Damato V, Theorell J, Al-Diwani A, et al. Rituximab abrogates aquaporin-4\u2013specific germinal center activity in patients with neuromyelitis optica spectrum disorders. Proc Natl Acad Sci U S A. 2022;119(24):e2121804119. https:\/\/doi.org\/10.1073\/pnas.2121804119.","DOI":"10.1073\/pnas.2121804119"},{"key":"907_CR145","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10184174","author":"MK Zarobkiewicz","year":"2021","unstructured":"Zarobkiewicz MK, Kowalska W, Morawska I, Halczuk P, Rejdak K, Bojarska-Junak A. IL-15 is overexpressed in \u03b3\u03b4 T\u00a0cells and correlates with disease severity in relapsing-remitting multiple sclerosis. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10184174.","journal-title":"J Clin Med"},{"key":"907_CR146","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jneuroim.2019.04.011","volume":"332","author":"AF Setiadi","year":"2019","unstructured":"Setiadi AF, Abbas AR, Jeet S, et al. IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis. J Neuroimmunol. 2019;332:147\u201354. https:\/\/doi.org\/10.1016\/j.jneuroim.2019.04.011.","journal-title":"J Neuroimmunol"},{"key":"907_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2024.102507","volume":"59","author":"Q Wang","year":"2024","unstructured":"Wang Q, Cheng Q, Yao G, et al. A cationic hydrogel with anti-IL-17A-specific nanobodies for rheumatoid arthritis treatment via inhibition of inflammatory activities of neutrophils. Nano Today. 2024;59:102507. https:\/\/doi.org\/10.1016\/j.nantod.2024.102507.","journal-title":"Nano Today"},{"key":"907_CR148","doi-asserted-by":"publisher","unstructured":"Fiocca Vernengo F, Beccaria CG, Araujo Furlan CL, et al. CD8(+) T cell immunity is compromised by anti-CD20 treatment and rescued by interleukin-17A. mBio. 2020;11(3):e00447-20. https:\/\/doi.org\/10.1128\/mBio.00447-20.","DOI":"10.1128\/mBio.00447-20"},{"issue":"5","key":"907_CR149","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/art.30292","volume":"63","author":"I Gutierrez-Roelens","year":"2011","unstructured":"Gutierrez-Roelens I, Galant C, Theate I, et al. Rituximab treatment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium. Arthritis Rheum. 2011;63(5):1246\u201354. https:\/\/doi.org\/10.1002\/art.30292.","journal-title":"Arthritis Rheum"},{"key":"907_CR150","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13080914","author":"C Guevara","year":"2024","unstructured":"Guevara C, Vicencio SC, Pizarro IS, et al. Evidence for TGF-\u03b21\/Nrf2 signaling crosstalk in a cuprizone model of multiple sclerosis. Antioxidants. 2024. https:\/\/doi.org\/10.3390\/antiox13080914.","journal-title":"Antioxidants"},{"issue":"3","key":"907_CR151","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1177\/135245859500100308","volume":"1","author":"M S\u00f6derstr\u00f6m","year":"1995","unstructured":"S\u00f6derstr\u00f6m M, Hillert J, Link J, Navikas V, Fredrikson S, Link H. Expression of IFN-gamma, IL-4, and TGF-beta in multiple sclerosis in relation to HLA-Dw2 phenotype and stage of disease. Mult Scler. 1995;1(3):173\u201380. https:\/\/doi.org\/10.1177\/135245859500100308.","journal-title":"Mult Scler"},{"key":"907_CR152","doi-asserted-by":"publisher","unstructured":"Hamaguchi M, Muramatsu R, Fujimura H, Mochizuki H, Kataoka H, Yamashita T. Circulating transforming growth factor-\u03b21 facilitates remyelination in the adult central nervous system. Elife. 2019;8:e41869. https:\/\/doi.org\/10.7554\/eLife.41869.","DOI":"10.7554\/eLife.41869"},{"key":"907_CR153","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3389\/fimmu.2015.00626","volume":"6","author":"R Li","year":"2015","unstructured":"Li R, Rezk A, Healy LM, et al. Cytokine-defined B cell responses as therapeutic targets in multiple sclerosis. Front Immunol. 2015;6:626. https:\/\/doi.org\/10.3389\/fimmu.2015.00626.","journal-title":"Front Immunol"},{"key":"907_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106540","volume":"100","author":"EM Khedr","year":"2025","unstructured":"Khedr EM, El-Deen HB, El-Mokhtar MA, Mahmoud DM. Decoding disease burden in multiple sclerosis: the role of IL-10 as biomarker of neuroinflammation and neurodegeneration. Mult Scler Relat Disord. 2025;100:106540. https:\/\/doi.org\/10.1016\/j.msard.2025.106540.","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"907_CR155","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13133-w","volume":"272","author":"L Davies","year":"2025","unstructured":"Davies L, Shehadeh R, Watkins WJ, Jolles S, Robertson NP, Tallantyre EC. Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis. J Neurol. 2025;272(6):415. https:\/\/doi.org\/10.1007\/s00415-025-13133-w.","journal-title":"J Neurol"},{"key":"907_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.106191","volume":"93","author":"K Smolik","year":"2025","unstructured":"Smolik K, Camilli F, Panzera I, et al. Hypogammaglobulinemia and severe infections in multiple sclerosis patients on anti-CD20 agents: a multicentre study. Mult Scler Relat Disord. 2025;93:106191. https:\/\/doi.org\/10.1016\/j.msard.2024.106191.","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"907_CR157","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200211","volume":"11","author":"A Langer-Gould","year":"2024","unstructured":"Langer-Gould A, Li BH, Smith JB, Xu S. Multiple sclerosis, rituximab, hypogammaglobulinemia, and risk of infections. Neurol Neuroimmunol Neuroinflamm. 2024;11(3):e200211. https:\/\/doi.org\/10.1212\/nxi.0000000000200211.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"12","key":"907_CR158","doi-asserted-by":"publisher","first-page":"7867","DOI":"10.4049\/jimmunol.175.12.7867","volume":"175","author":"R Ettinger","year":"2005","unstructured":"Ettinger R, Sims GP, Fairhurst AM, et al. IL-21 induces differentiation of human naive and memory B\u00a0cells into antibody-secreting plasma cells. J Immunol. 2005;175(12):7867\u201379. https:\/\/doi.org\/10.4049\/jimmunol.175.12.7867.","journal-title":"J Immunol"},{"issue":"8","key":"907_CR159","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/icb.2012.17","volume":"90","author":"SA Diehl","year":"2012","unstructured":"Diehl SA, Schmidlin H, Nagasawa M, Blom B, Spits H. IL-6 triggers IL-21 production by human CD4+ T\u00a0cells to drive STAT3-dependent plasma cell differentiation in B\u00a0cells. Immunol Cell Biol. 2012;90(8):802\u201311. https:\/\/doi.org\/10.1038\/icb.2012.17.","journal-title":"Immunol Cell Biol"},{"issue":"4","key":"907_CR160","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/1744666x.2019.1562905","volume":"15","author":"F Paul","year":"2019","unstructured":"Paul F, Cartron G. Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Rev Clin Immunol. 2019;15(4):383\u20139. https:\/\/doi.org\/10.1080\/1744666x.2019.1562905.","journal-title":"Expert Rev Clin Immunol"},{"key":"907_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109688","volume":"253","author":"T Chitnis","year":"2023","unstructured":"Chitnis T, Foley J, Ionete C, et al. Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis. Clin Immunol. 2023;253:109688. https:\/\/doi.org\/10.1016\/j.clim.2023.109688.","journal-title":"Clin Immunol"},{"key":"907_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.110262","volume":"264","author":"S El Mahdaoui","year":"2024","unstructured":"El Mahdaoui S, Hansen MM, Hansen MB, et al. Effects of anti-CD20 therapy on circulating and intrathecal follicular helper T\u00a0cell subsets in multiple sclerosis. Clin Immunol. 2024;264:110262. https:\/\/doi.org\/10.1016\/j.clim.2024.110262.","journal-title":"Clin Immunol"},{"key":"907_CR163","doi-asserted-by":"publisher","DOI":"10.3390\/cells14070552","author":"AG Willison","year":"2025","unstructured":"Willison AG, Hagler R, Weise M, et al. Effects of anti-CD20 antibody therapy on immune cell dynamics in relapsing-remitting multiple sclerosis. Cells. 2025. https:\/\/doi.org\/10.3390\/cells14070552.","journal-title":"Cells"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00907-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00907-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00907-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:07:51Z","timestamp":1778681271000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00907-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":163,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["907"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00907-1","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Michael Unterhofer received travel support and has participated in meetings sponsored by Alexion Pharmaceuticals, Merck, Neuraxpharm and Novartis. Peter Wipfler has received personal honoraria for lectures and educational activities from Alexion, Biogen, Merck, Neuraxpharm, Novartis, Roche, Sanofi-Genzyme, Teva-Ratiopharm, Janssen-Pharmazeutika, Bristol Myers Squibb and Horizon Therapeutics. Andrea Harrer received lecture honoraria from Merck, travel and research support from BMS. Tobias Moser received travel support, honoraria for presentations or participation on advisory boards from Biogen, BMS, Novartis, Roche, Sanofi, Merck, Stada and Teva. Marc Messner and Josef-Martin Mitterwallner declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}